Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspen vs REMEVi

Aspen
Graded #372

Lower grade

vs+15.100000000000001
REMEVi
Graded #70

Higher grade

The verdict

REMEVi takes it — 73.5/100 to 58.4/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +30
27
57
Dose & formulationREMEVi +19
64
83
Clinical oversightREMEVi +6
80
86
Labs & monitoringREMEVi +3
52
55
FulfillmentREMEVi +3
94
97
Contract termsREMEVi +22
47
69
Aspen · left barREMEVi · right bar

The numbers

MetricAspenREMEVi
WeighScore58.4/10073.5/100
GradeCC
Scorecard rank#372#70
Semaglutide$279/mo (3-month plan, compounded)$219/mo
Tirzepatide$399/mo (compounded)$319/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Aspen

Graded #372 · C

Strengths

  • LegitScript-certified with an independently verifiable seal (#50306023) and HIPAA compliance — a strong trust signal for a compounded-GLP-1 telehealth
  • Names its dispensing pharmacy: Red Rock Compounding Pharmacy, LegitScript-certified and NABP-accredited, licensed in 49 states plus DC
  • Flat pricing at every dose ("same price at every dose, no surprises") plus free expedited shipping, so your cost won't rise as you titrate up
  • Competitive prepay rates — compounded semaglutide as low as $179/mo (12-mo) and tirzepatide $299/mo — with zero interest and no credit check
  • Money-back guarantee for qualifying patients who complete the full 28-week program without losing weight; available in all 50 states + DC

Where it loses points

  • Compounded semaglutide and tirzepatide only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • Even the "monthly" plan requires a 3-month commitment with three months of medication shipped and billed upfront — limited month-to-month flexibility
  • Standing month-to-month pricing is steep ($279 semaglutide, $399 tirzepatide); the lowest rates require 6- or 12-month prepay
  • The provider chooses semaglutide vs tirzepatide for you, so you can't freely pick your own molecule
  • Registered as Aspen Health Systems LLC at a Sheridan, WY address; async model with no routine video visit
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard